AbbVie – Health

AbbVie settles trade secrets fight with Evolus, scoring $35M and royalties on Botox rival Jeuveau

AbbVie’s newest revenue streams come courtesy of Evolus and its Botox competitor Jeuveau. To settle a long-running legal battle, Evolus will pay Allergan and its partner Medytox $ 35 million in cash, plus royalties on Jeuveau’s U.S. sales, according an Evolus SEC filing. The settlement ends all legal claims the trio had levied against one another… Read More »

AbbVie touts Humira defense strategy abroad as a positive sign for forthcoming U.S. battle

AbbVie’s strength has long been tied to the performance of megablockbuster Humira, which is facing an existential threat as U.S. copycats creep closer. Despite a “more aggressive” than expected biosimilar challenge abroad, AbbVie believes its defense strategy—and lessons learned—will help it weather the storm. In an earnings call with analysts Friday, AbbVie CEO Rick Gonzalez touted the drugmaker’s… Read More »